CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 121 enrolled
Drug / intervention
Trifarotene Cream +1 moredrug
Likely dose
Trifarotene Cream 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04856904
NCT04856904Phase 4Completed
CompareCT.gov

Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks

Galderma R&D·interventional·Posted Apr 23, 2021·Updated Jun 11, 2024

In Brief

A Phase 4 clinical trial evaluating Trifarotene Cream and Trifarotene Vehicle Cream for Acne Vulgaris. Completed, enrolled 121 participants across 18 sites in 3 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, France, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedApr 23, 2021
Enrollment StartMay 28, 2021
Primary CompletionFeb 8, 2023
Study CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.2 years ago

Interventions

Trifarotene Creamdrug

Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks

Trifarotene Vehicle Creamdrug

Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks